Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1988-6-20
|
| pubmed:abstractText |
One hundred five patients with peritonitis were randomized to receive either tobramycin sulfate plus clindamycin phosphate or moxalactam alone before surgical intervention. Fifty-nine patients were evaluable. A mean of 3.1 (moxalactam) and 3.5 (tobramycin-clindamycin) pathogens per patient were identified. Overall success rate was 85% (tobramycin-clindamycin, 24/30; moxalactam, 26/29). When patients with appendicitis were excluded, there was an observed but not statistically significant advantage of moxalactam over tobramycin-clindamycin (85% vs 67%). There were five deaths (tobramycin-clindamycin, four; moxalactam, one). Other complications included hypoprothrombinemia (tobramycin-clindamycin, five; moxalactam, five), renal dysfunction (tobramycin-clindamycin, three; moxalactam, one), and superinfection (tobramycin-clindamycin, nine; moxalactam, six). More wound infections were noted in the group given tobramycin-clindamycin. These data suggest that moxalactam is as safe and efficacious as tobramycin plus clindamycin. The observed benefits of this agent warrant study in a larger sample to verify advantages of moxalactam over combination therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0004-0010
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
123
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
714-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3285809-Abscess,
pubmed-meshheading:3285809-Adolescent,
pubmed-meshheading:3285809-Adult,
pubmed-meshheading:3285809-Bacteroides Infections,
pubmed-meshheading:3285809-Clindamycin,
pubmed-meshheading:3285809-Clinical Trials as Topic,
pubmed-meshheading:3285809-Combined Modality Therapy,
pubmed-meshheading:3285809-Drug Therapy, Combination,
pubmed-meshheading:3285809-Escherichia coli Infections,
pubmed-meshheading:3285809-Humans,
pubmed-meshheading:3285809-Hypoprothrombinemias,
pubmed-meshheading:3285809-Infant, Newborn,
pubmed-meshheading:3285809-Middle Aged,
pubmed-meshheading:3285809-Moxalactam,
pubmed-meshheading:3285809-Peritonitis,
pubmed-meshheading:3285809-Premedication,
pubmed-meshheading:3285809-Prospective Studies,
pubmed-meshheading:3285809-Random Allocation,
pubmed-meshheading:3285809-Sepsis,
pubmed-meshheading:3285809-Streptococcal Infections,
pubmed-meshheading:3285809-Surgical Wound Infection,
pubmed-meshheading:3285809-Tobramycin
|
| pubmed:year |
1988
|
| pubmed:articleTitle |
Moxalactam vs tobramycin-clindamycin. A randomized trial in secondary peritonitis.
|
| pubmed:affiliation |
Department of Surgery, University Hospitals of Cleveland, OH 44106.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Review,
Research Support, Non-U.S. Gov't
|